Compare Revvity Inc (RVTY) vs Royal Bank of Canada (RY) Price & Performance

RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.

RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.

Royal Bank of Canada (RY) trades at $190.56, down 2.95% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 beating estimates of $2.89 (Zacks Investment Research, August 27, 2026). Revenue growth accelerated to $66.53B in 2025, with net income margin improving to 32.01%. The company maintains a solid dividend payout of $1.76 per share, with the next payment scheduled for November 24, 2026.

RY presents a mixed investment case with strong profitability and dividend stability offset by stretched valuations and bearish technical indicators. The 17.2 P/E ratio suggests fair valuation, while analyst consensus leans neutral with 43% buy ratings. Key risks include macroeconomic sensitivity and competitive pressures in financial services. The stock's current technical weakness near support at $189 may present entry opportunities for long-term investors seeking quality banking exposure.